WallStSmart

Cencora Inc. (COR)vsWest Pharmaceutical Services Inc (WST)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Cencora Inc. generates 10498% more annual revenue ($325.78B vs $3.07B). WST leads profitability with a 16.1% profit margin vs 0.5%. COR appears more attractively valued with a PEG of 0.78. COR earns a higher WallStSmart Score of 62/100 (C+).

COR

Buy

62

out of 100

Grade: C+

Growth: 6.7Profit: 6.0Value: 7.3Quality: 5.0

WST

Buy

55

out of 100

Grade: C-

Growth: 4.7Profit: 8.0Value: 4.7Quality: 7.3
Piotroski: 5/9Altman Z: 4.91
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

CORSignificantly Overvalued (-43.9%)

Margin of Safety

-43.9%

Fair Value

$254.20

Current Price

$325.08

$70.88 premium

UndervaluedFair: $254.20Overvalued
WSTSignificantly Overvalued (-256.8%)

Margin of Safety

-256.8%

Fair Value

$68.99

Current Price

$247.02

$178.03 premium

UndervaluedFair: $68.99Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

COR3 strengths · Avg: 9.0/10
Return on EquityProfitability
133.5%10/10

Every $100 of equity generates 134 in profit

Market CapQuality
$63.59B9/10

Large-cap with strong market position

PEG RatioValuation
0.788/10

Growing faster than its price suggests

WST2 strengths · Avg: 9.0/10
Altman Z-ScoreHealth
4.9110/10

Safe zone — low bankruptcy risk

Operating MarginProfitability
21.6%8/10

Strong operational efficiency at 21.6%

Areas to Watch

COR4 concerns · Avg: 3.0/10
P/E RatioValuation
39.2x4/10

Premium valuation, high expectations priced in

Profit MarginProfitability
0.5%3/10

0.5% margin — thin

Operating MarginProfitability
1.2%3/10

Operating margin of 1.2%

Price/BookValuation
33.1x2/10

Trading at 33.1x book value

WST3 concerns · Avg: 3.3/10
P/E RatioValuation
36.1x4/10

Premium valuation, high expectations priced in

EPS GrowthGrowth
2.1%4/10

2.1% earnings growth

PEG RatioValuation
2.892/10

Expensive relative to growth rate

Comparative Analysis Report

WallStSmart Research

Bull Case : COR

The strongest argument for COR centers on Return on Equity, Market Cap, PEG Ratio. PEG of 0.78 suggests the stock is reasonably priced for its growth.

Bull Case : WST

The strongest argument for WST centers on Altman Z-Score, Operating Margin. Profitability is solid with margins at 16.1% and operating margin at 21.6%.

Bear Case : COR

The primary concerns for COR are P/E Ratio, Profit Margin, Operating Margin. Thin 0.5% margins leave little buffer for downturns.

Bear Case : WST

The primary concerns for WST are P/E Ratio, EPS Growth, PEG Ratio.

Key Dynamics to Monitor

COR profiles as a value stock while WST is a mature play — different risk/reward profiles.

WST carries more volatility with a beta of 1.18 — expect wider price swings.

WST is growing revenue faster at 7.5% — sustainability is the question.

WST generates stronger free cash flow (175M), providing more financial flexibility.

Bottom Line

COR scores higher overall (62/100 vs 55/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Cencora Inc.

HEALTHCARE · MEDICAL DISTRIBUTION · USA

CoreSite Realty Corporation (NYSE: COR) delivers secure, reliable, high-performance data center, cloud access and interconnect solutions to a growing client ecosystem in eight key North American markets.

West Pharmaceutical Services Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

West Pharmaceutical Services, Inc. is a designer and manufacturer of injectable pharmaceutical packaging and delivery systems. The company is headquartered in Exton, Pennsylvania.

Want to dig deeper into these stocks?